Abstracts Archive - Page 806 of 2607 - ACR Meeting Abstracts

Abstract Number: 1513 • ACR Convergence 2021
Control of T Cell Tolerance by the NR4A Family of Nuclear Receptors
Ryosuke Hiwa¹, Hailyn Nielsen¹, James Mueller¹ and Julie Zikherman², ¹University of California San Francisco, San Francisco, CA, ²UCSF Medical Center, San Francisco, CA
Background/Purpose: Current therapies for autoimmune disease often lead to treatment-limiting immunosuppression. Selective manipulation of antigen (Ag)-specific immune responses could enhance our therapeutic approach. Targeting members…
Abstract Number: 1514 • ACR Convergence 2021
Age-related Metabolic Reprogramming of Memory CD4+ T Cells Is Associated with Reactive Oxygen Species-induced Immune Cell Dysfunction
Yuling Chen¹, Pierre-Louis Krau², Pelle Löwe³, Moritz Pfeiffenberger⁴, Lisa Ehlers³, Alexandra Damerau⁴, Paula Hoff³, Frank Buttgereit⁵ and Timo Gaber⁴, ¹Charité University Medicine Berlin, Berlin, Germany, ²Charit Universittsmedizin Berlin, corporate member of Freie Universitt Berlin, Humboldt-Universitt zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ³Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁵Charité – Universitätsmedizin Berlin, Berlin, Germany
Background/Purpose: Inflamm-aging is a sterile, low-grade, chronic systemic inflammatory state characterized by an increase in proinflammatory cytokines involved in the development of most age-related diseases…
Abstract Number: 1515 • ACR Convergence 2021
Programmed Cell Death Protein 1 (PD-1)-Expressing CD4+ T Cells Are Expanded in Early Rheumatoid Arthritis and Correlate with Response to Treatment
Katie Williams¹, Annabelle Small², Qingxuan Song³, Suzanne Cole⁴, Ling-yang hao⁵, William Murray-Brown⁶, Susanna Proudman⁷, Malcolm Smith⁸, Sunil Nagpal⁹ and Mihir Wechalekar¹⁰, ¹Flinders University, Adelaide, Australia, ²Flinders University, Bedford Park, Australia, ³Janssen Research & Development LLC, Spring House, PA, ⁴Janssen Research, Adelaide, Australia, ⁵Janssen Research, Philadelphia, PA, ⁶GlaxoSmithKline, Adelaide, Australia, ⁷University of Adelaide, Medindie, Australia, ⁸Flinders Medical Centre, Adelaide, Australia, ⁹Janssen Research, Collegeville, PA, ¹⁰Flinders Medical Centre, Bedford Park, Australia
Background/Purpose: Programmed death protein 1 (PD-1) expressing T cells, including T follicular and T peripheral helper cells, are expanded in the circulation of individuals with…
Abstract Number: 1516 • ACR Convergence 2021
Clinical Phenotypes and Treatment of Rheumatic Immune-Related Adverse Events from Checkpoint Inhibitors: A Retrospective Cohort of 112 Patients
Tiphaine Lenfant¹, Yuxuan Jin², Elizabeth Kirchner³, Pauline Funchain², Jung-Min Song², Moshe Ornstein², Laura Wood², Donald Eicher², Rula Hajj-Ali⁴, Leonard Calabrese² and Cassandra Calabrese⁵, ¹Institut Mutualiste Montsouris, Paris, France, ²Cleveland Clinic, Cleveland, OH, ³CCF, Cleveland, OH, ⁴Cleveland Clinic, Hunting Valley, OH, ⁵Cleveland Clinic Foundation, Cleveland Heights, OH
Background/Purpose: To describe a single center cohort of rheumatic immune related adverse events (irAEs) observed in patients treated with checkpoint inhibitor therapy (ICI) and to…
Abstract Number: 1517 • ACR Convergence 2021
Prevalence of Autoantibodies in Patients with Melanoma Who Develop Rheumatic Immune Related Adverse Events During Treatment with Immune Checkpoint Blockade
Sophia Weinmann¹, Amanda Eudy² and David Pisetsky¹, ¹Duke University Medical Center, Durham, NC, ²Duke University, Durham, NC
Background/Purpose: Patients with malignancy who develop rheumatic immune related adverse events (IRAEs) during immune checkpoint blockade (ICB) are commonly autoantibody negative. The change from chemotherapy…
Abstract Number: 1518 • ACR Convergence 2021
Elucidating Activated Osteoarthritis as an Emerging Immune Checkpoint Inhibitor Toxicity: A Descriptive Observational Study
Pankti Reid¹, David Liew², Rajshi Akruwala³, Anne Bass⁴ and Karmela Kim Chan⁵, ¹University of Chicago Medical Center, Chicago, IL, ²Austin Health, Heidelberg, Australia, ³SUNY Downstate Health Sciences University College of Medicine, Brooklyn, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICIs) are a type of immunotherapy used for cancer management. ICI toxicities can challenge the ability to safely continue ICI therapy…
Abstract Number: 1519 • ACR Convergence 2021
Concomitant Targeted Therapy with Ongoing Immune Checkpoint Inhibitor (ICI) Therapy for Severe Immune Related Adverse Events (irAEs): Clinical Experience from Two Centers
Cassandra Calabrese¹, Khashayar Esfahani² and Leonard Calabrese³, ¹Cleveland Clinic Foundation, Cleveland Heights, OH, ²Jewish General Hospital, Department of Oncology, McGill University, Montréal, QC, Canada, ³Cleveland Clinic, Cleveland, OH
Background/Purpose: Treatment of irAEs is a balance of suppressing irAE-associated hyper-inflammation without inhibiting anti-tumoral effects of ICI. Treatment of grade 3/4 irAEs is most challenging…
Abstract Number: 1520 • ACR Convergence 2021
Do Specific Rheumatic Autoantibodies Predict Severity or Time to Onset of Immune-related Adverse Events from Checkpoint Inhibitors?
Nilasha Ghosh¹, Deanna Jannat-Khah², Karmela Kim Chan², Michael Postow³ and Anne Bass⁴, ¹Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Memorial Sloane Kettering Cancer Center, New York, NY, ⁴Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) are a novel cancer therapeutic that have had a dramatic impact on treating advanced malignancies by enhancing the anti-tumor T…
Abstract Number: 1521 • ACR Convergence 2021
Autoantibody Microarray Signal Intensities May Predict the Occurrence of Immune-related Adverse Events
Nilasha Ghosh¹, Chengsong Zhu², Karmela Kim Chan³, Michael Postow⁴ and Anne Bass⁵, ¹Hospital for Special Surgery, New York, NY, ²UT Southwestern, Dallas, TX, ³Hospital for Special Surgery, New York, NY, ⁴Memorial Sloane Kettering Cancer Center, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) are a novel cancer therapeutic that have had a dramatic impact on treating advanced malignancies by enhancing the anti-tumor T…
Abstract Number: 1522 • ACR Convergence 2021
Potential Predictors of Persistence in Immune Check Point Inhibitor Induced Arthritis
Anu Desai¹, Lakshmi Priya Shadananan¹, Adam Croft², Lalit Pallan¹, Neil Steven³ and Benjamin Fisher⁴, ¹University of Birmingham, Birmingham, United Kingdom, ²University of Birmingham, Halesowen, United Kingdom, ³Institute of Immunology and Immunotherapy/University of Birmingham, Birmingham, United Kingdom, ⁴Institute of Inflammation and Ageing, College of Medical and Dental Sciences, University of Birmingham; National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: Immune Check Point Inhibitors (ICIs) are widely used in Oncology and are associated with multiple autoimmune and systemic inflammatory reactions called immune-related adverse events.…
Abstract Number: 1523 • ACR Convergence 2021
Outcomes and Disease Characteristics in Patients with Rheumatoid Arthritis Treated with Immune Checkpoint Inhibitors for Malignancy at a Single Academic Institution
Megan Hansen, Danny Zakria and Douglas Johnson, Vanderbilt University Medical Center, Nashville, TN
Background/Purpose: Since the introduction of the first immune checkpoint inhibitor (ICI) in 2011, they have become widely utilized in the treatment of malignancy. It is…
Abstract Number: 1524 • ACR Convergence 2021
COVID-19 Vaccination Rates and Adverse Events Among Patients on Immunosuppressive Therapy in the Rheumatology Clinic Caring for an Underserved Population
Suguni Gallappaththy¹, Sarah Ifteqar² and Amr Edrees³, ¹University of Missouri Kansas City, Kansas City, KS, ²UMKC, Kansas City, MO, ³UMKC, Overland Park, KS
Background/Purpose: Patients with autoimmune inflammatory rheumatic disease (AIRD) are at a higher risk for serious infections due to a combination of disease related immune dysfunction…
Abstract Number: 1525 • ACR Convergence 2021
Risk Factors for Anti-infliximab Antibody Formation: Results from a Randomized Controlled Trial
Marthe Brun¹, Guro Goll¹, Kristin Jørgensen², Joseph Sexton¹, Johanna Gehin³, Øystein Sandanger⁴, Inge Olsen⁴, Rolf Anton Klaasen⁴, David Warren⁴, Cato Mørk⁵, Tore Kvien¹, Jørgen Jahnsen², Nils Bolstad⁴, Espen Haavardsholm¹ and Silje Watterdal Syversen¹, ¹Diakonhjemmet Hospital, Oslo, Norway, ²Akershus University Hospital, Lørenskog, Norway, ³Oslo University Hospital, Lillehammer, Nepal, ⁴Oslo University Hospital, Oslo, Norway, ⁵Akershus Dermatology Center, Lørenskog, Norway
Background/Purpose: Immunogenicity is related to loss of efficacy and safety to TNFα inhibitors and is frequently observed early in the treatment course. The highest rate…
Abstract Number: 1526 • ACR Convergence 2021
Development of Antinuclear Antibodies and Systemic Lupus Erythematosus in Patients on Tumor Necrosis Factor α Inhibitor Therapy
Chathura Wijewardena¹, Paramarajan Pirinavan¹, Sandy Nasr¹ and Andras Perl², ¹SUNY Upstate Medical University, Syracuse, NY, ²State University of New York, Syracuse, NY
Background/Purpose: Tumor necrosis factor α (TNF-α) inhibitor therapy has been widely used worldwide as a potent immunosuppressant for a variety of rheumatological diseases. Induction of…
Abstract Number: 1527 • ACR Convergence 2021
Effect of Rituximab on IgG Levels and Associated Infection Risk in Myositis
Michael Macklin¹, Chester Oddis², Siamak Moghadam-Kia², Dana Ascherman² and Rohit Aggarwal², ¹University of Pittsburgh, Pittsburgh, ²University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rituximab is an anti-CD20 antibody with therapeutic use in myositis. However, given its B cell depleting mechanism, there is concern regarding its association with…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].